Britain's medicines regulator on Friday approved Novavax's (NVAX.O) COVID-19 vaccine for children aged between 12 and 17 years.
The mRNA
vaccines made by Moderna as well as the partnership between
Pfizer-
BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
Britain in February cleared Novavax's two-dose
vaccine, Nuvaxovid, for use in adults.
